keyword
MENU ▼
Read by QxMD icon Read
search

liver trials cancer

keyword
https://www.readbyqxmd.com/read/29650688/outcomes-of-elderly-patients-with-advanced-soft-tissue-sarcoma-treated-with-first-line-chemotherapy-a-pooled-analysis-of-12-eortc-soft-tissue-and-bone-sarcoma-group-trials
#1
Eugenie Younger, Saskia Litière, Axel Le Cesne, Olivier Mir, Hans Gelderblom, Antoine Italiano, Sandrine Marreaud, Robin Lewis Jones, Alessandro Gronchi, Winette T A van der Graaf
BACKGROUND: Almost half of patients diagnosed with soft tissue sarcoma (STS) are older than 65 years; however, the outcomes of elderly patients with metastatic disease are not well described. PATIENTS AND METHODS: An elderly cohort of patients aged ≥65 years was extracted from the European Organization for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group database of patients treated with first-line chemotherapy for advanced STS within 12 EORTC clinical trials...
April 12, 2018: Oncologist
https://www.readbyqxmd.com/read/29650363/chemotherapy-versus-chemoradiotherapy-after-surgery-and-preoperative-chemotherapy-for-resectable-gastric-cancer-critics-an-international-open-label-randomised-phase-3-trial
#2
Annemieke Cats, Edwin P M Jansen, Nicole C T van Grieken, Karolina Sikorska, Pehr Lind, Marianne Nordsmark, Elma Meershoek-Klein Kranenbarg, Henk Boot, Anouk K Trip, H A Maurits Swellengrebel, Hanneke W M van Laarhoven, Hein Putter, Johanna W van Sandick, Mark I van Berge Henegouwen, Henk H Hartgrink, Harm van Tinteren, Cornelis J H van de Velde, Marcel Verheij
BACKGROUND: Both perioperative chemotherapy and postoperative chemoradiotherapy improve survival in patients with resectable gastric cancer from Europe and North America. To our knowledge, these treatment strategies have not been investigated in a head to head comparison. We aimed to compare perioperative chemotherapy with preoperative chemotherapy and postoperative chemoradiotherapy in patients with resectable gastric adenocarcinoma. METHODS: In this investigator-initiated, open-label, randomised phase 3 trial, we enrolled patients aged 18 years or older who had stage IB- IVA resectable gastric or gastro-oesophageal adenocarcinoma (as defined by the American Joint Committee on Cancer, sixth edition), with a WHO performance status of 0 or 1, and adequate cardiac, bone marrow, liver, and kidney function...
April 9, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29649683/modulation-of-udp-glucuronidation-by-acridinone-antitumor-agents-c-1305-and-c-1311-in-hepg2-and-ht29-cell-lines-despite-slight-impact-in-noncellular-systems
#3
Anna Bejrowska, Monika Pawłowska, Anna Mróz, Zofia Mazerska
BACKGROUND: Among the studied antitumor acridinone derivatives developed in our laboratory, 5-dimethylaminopropylamino-8-hydroxytriazoloacridinone (C-1305) and 5-diethylaminoethylamino-8-hydroxyimidazoacridinone (C-1311) exhibited cytotoxic and antitumor properties against several cancer types and were selected to be evaluated in preclinical and early-phase clinical trials. In the present work, we investigated the impact of C-1305 and C-1311 on UDP-glucuronosyltransferase (UGT) activity...
November 22, 2017: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/29629806/comparative-effectiveness-of-transarterial-embolization-and-sorafenib-for-hepatocellular-carcinoma-a-population-based-study
#4
Sharon W Kwan, William P Harris, Laura S Gold, Paul L Hebert
OBJECTIVE: The purpose of this study was to compare the clinical effectiveness of embolization with that of sorafenib in the management of hepatocellular carcinoma as practiced in real-world settings. MATERIALS AND METHODS: This population-based observational study was conducted with the Surveillance, Epidemiology, and End Results-Medicare linked database. Patients 65 years old and older with a diagnosis of primary liver cancer between 2007 and 2011 who underwent embolization or sorafenib treatment were identified...
April 9, 2018: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/29626465/adjuvant-androgen-deprivation-therapy-following-prostate-total-cryoablation-in-high-risk-localized-prostate-cancer-patients-open-labeled-randomized-clinical-trial
#5
Chung-Hsin Chen, Yeong-Shiau Pu
PURPOSE: To investigate the efficacy and safety profile of 12-month adjuvant androgen-deprivation therapy (ADT) following total-gland cryoablation (TGC) in patients with high-risk localized prostate cancer (HRLPC). MATERIALS AND METHODS: This open-label randomized trial included 38 HRLPC patients who received TGC between July 2011 and March 2013. Within 4 weeks after TGC, subjects were randomly assigned (1:1) to either the 12-month adjuvant ADT or non-adjuvant ADT group...
April 4, 2018: Cryobiology
https://www.readbyqxmd.com/read/29623268/the-new-era-of-transplant-oncology-liver-transplantation-for-nonresectable-colorectal-cancer-liver-metastases
#6
REVIEW
Andre Gorgen, Hala Muaddi, Wei Zhang, Ian McGilvray, Steven Gallinger, Gonzalo Sapisochin
Colorectal cancer (CRC) is the third most incident cancer worldwide. Most of CRC patients will develop distant metastases, mainly to the liver, and liver resection is the only potential chance for cure. On the other hand, only a small proportion of patients with hepatic CRC metastasis are candidates for upfront liver resection. Liver transplantation (LT) is an attractive option for patients with nonresectable CRC liver metastases (NRCLM) without extrahepatic involvement. Initial experiences with LT for NRCLM achieved very poor outcomes, with a 5-year overall survival (OS) lower than 20%...
2018: Canadian Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29623266/the-potential-role-of-liver-transplantation-as-a-treatment-option-in-colorectal-liver-metastases
#7
REVIEW
Pål-Dag Line, Morten Hagness, Svein Dueland
Liver resection is the only potentially curative treatment option in patients with liver metastases from colorectal cancer, but only about 20% of the patients are resectable. Liver transplantation of patients with unresectable liver metastases was attempted in the early era but it was abandoned due to poor survival. During the last decade, several case reports, a controlled pilot study, and a retrospective cohort study indicated that prolonged disease-free survival and overall survival can be obtained in a proportion of these patients...
2018: Canadian Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29623110/clinical-assessment-of-immune-related-adverse-events
#8
REVIEW
Aaron Sosa, Esther Lopez Cadena, Cristina Simon Olive, Niki Karachaliou, Rafael Rosell
Immunotherapy through checkpoint inhibitors is now standard practice for a growing number of cancer types, supported by overall improvement of clinical outcomes and better tolerance. One anti-CTLA-4 antibody (ipilimumab), two anti-PD-1 antibodies (pembrolizumab and nivolumab) and three anti-PD-L1 antibodies (atezolizumab, avelumab and durvalumab) have been approved for clear benefits across diverse trials. Adverse events of an immune nature associated with these agents frequently affect the skin, colon, endocrine glands, lungs and liver...
2018: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/29604436/investigational-chemotherapy-and-novel-pharmacokinetic-mechanisms-for-the-treatment-of-breast-cancer-brain-metastases
#9
REVIEW
Neal Shah, Afroz S Mohammad, Pushkar Saralkar, Samuel A Sprowls, Schuyler D Vickers, Devin John, Rachel M Tallman, Brandon Lucke-Wold, Katherine E Jarrell, Mark Pinti, Richard L Nolan, Paul R Lockman
In women, breast cancer is the most common cancer diagnosis and second most common cause of cancer death. More than half of breast cancer patients will develop metastases to the bone, liver, lung, or brain. Breast cancer brain metastases (BCBM) confers a poor prognosis, as current therapeutic options of surgery, radiation, and chemotherapy rarely significantly extend life and are considered palliative. Within the realm of chemotherapy, the last decade has seen an explosion of novel chemotherapeutics involving targeting agents and unique dosage forms...
March 28, 2018: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/29593893/identifying-and-managing-the-adverse-effects-of-immune-checkpoint-blockade
#10
REVIEW
Arthur Winer, J Nicholas Bodor, Hossein Borghaei
Immunotherapy has revolutionized the field of oncology. By inhibiting the cytotoxic T-lymphocyte-associated protein (CTLA-4) and programmed death-1 (PD-1) immune checkpoint pathways, multiple studies have demonstrated greatly improved survival in locally advanced and metastatic cancers including melanoma, renal, lung, gastric, and hepatocellular carcinoma. Trials in other malignancies are ongoing, and undoubtedly the number of drugs in this space will grow beyond the six currently approved by the Food and Drug Administration...
February 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29589077/-surgical-treatment-of-peritoneal-metastases-of-colorectal-cancer
#11
REVIEW
S Schüle, H Mothes, U Settmacher, J Zanow
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) may significantly improve overall survival in selected patients with peritoneal metastases of colorectal cancer. For good oncological results complete macroscopic cytoreduction is crucial; furthermore, a linear correlation between peritoneal tumor load, as determined by the peritoneal cancer index (PCI) and overall survival has been demonstrated; therefore, surgical treatment should be initiated as early as possible. Synchronous resection of up to three liver metastases may be performed safely and with good results and no influence on the morbidity...
March 27, 2018: Der Chirurg; Zeitschrift Für Alle Gebiete der Operativen Medizen
https://www.readbyqxmd.com/read/29587697/association-between-skirt-size-and-chronic-liver-disease-in-post-menopausal-women-a-prospective-cohort-study-within-the-united-kingdom-trial-of-ovarian-cancer-screening-ukctocs
#12
P M Trembling, S Apostolidou, A Gentry-Maharaj, J Parkes, A Ryan, S Tanwar, M Burnell, U Menon, W M Rosenberg
BACKGROUND: We investigated the association between self-reported skirt size (SS) and change in SS, and incidence of chronic liver disease (CLD) in a prospective cohort study of women recruited to the UKCTOCS trial. METHODS: Women recruited to UKCTOCS in England without documented CLD self-reported their current UK SS during trial participation and were asked to recall their SS when aged in 20s (via completion of a questionnaire 3-5 years after recruitment). Participants were followed up via electronic health record linkage and hazard ratios (HR) calculated for incident liver-related events (LRE)...
March 27, 2018: BMC Public Health
https://www.readbyqxmd.com/read/29570376/best-protocol-for-combined-contrast-enhanced-thoracic-and-abdominal-ct-for-lung-cancer-a-single-institution-randomized-crossover-clinical-trial
#13
Elena García-Garrigós, Juan José Arenas-Jiménez, José Sánchez-Payá
OBJECTIVE: The purpose of this study was to evaluate the superiority of either of two protocols for combined contrast-enhanced thoracic and abdominal CT of patients with lung cancer by comparing contrast enhancement, contrast-related artifacts, image quality, and radiation dose. SUBJECTS AND METHODS: In this randomized controlled crossover clinical trial, 77 patients who underwent 203 CT examinations were enrolled. All patients underwent at least two examinations performed with both protocols...
March 23, 2018: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/29564186/immunomodulation-in-hepatocellular-cancer
#14
REVIEW
Sunyoung Lee, Matthew Loecher, Renuka Iyer
Hepatocellular carcinoma (HCC) is the fastest growing malignancy in the United States in relation to mortality. HCC relies on a complex immunosuppressive network to modify the host immune system and evade destruction. Intrinsic to the liver's function and anatomy, native hepatic and immune cells produce many inhibitory cytokines that promote tolerogenicity and limit immune response. Since the introduction of sorafenib in 2008, no treatment has been able to demonstrate improved survival in patients with advanced HCC post disease progression treated with sorafenib...
February 2018: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29559215/casticin-from-vitex-species-a-short-review-on-its-anticancer-and-anti-inflammatory-properties
#15
REVIEW
Eric Wei Chiang Chan, Siu Kuin Wong, Hung Tuck Chan
This short review provides an update of the anticancer and anti-inflammatory properties of casticin from Vitex species. Casticin is a polymethylflavone with three rings, an orthocatechol moiety, a double bond, two hydroxyl groups and four methoxyl groups. Casticin has been isolated from various tissues of plants in the Vitex genus: fruits and leaves of V. trifolia; aerial parts and seeds of V. agnus-castus and leaves of V. negundo. Studies have reported the antiproliferative and apoptotic activities of casticin from Vitex species...
March 6, 2018: Journal of Integrative Medicine
https://www.readbyqxmd.com/read/29545575/efficacy-and-safety-of-apatinib-in-patients-with-previously-treated-metastatic-colorectal-cancer-a-real-world-retrospective-study
#16
Miaomiao Gou, Haiyan Si, Yong Zhang, Niansong Qian, Zhikuan Wang, Weiwei Shi, Guanghai Dai
No definitive treatment strategy has been established for patients with metastatic colorectal cancer (mCRC) who experienced progression after three or more lines of chemotherapy. A total of 36 mCRC patients were enrolled in this retrospective study who received apatinib therapy under non-clinical trial setting after progression in People's liberation army general Hospital from March 2015 and August 2017. Progression free survival (PFS), overall survival (OS), disease control rate (DCR), objective response rate (ORR) and treatment-related adverse events (AEs) were reviewed and evaluated...
March 15, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29543988/hepatic-resection-compared-to-chemoembolization-in-intermediate-to-advanced-stage-hepatocellular-carcinoma-a-meta-analysis-of-high-quality-studies
#17
Myung Han Hyun, Young-Sun Lee, Ji Hoon Kim, Chan Uk Lee, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun
According to the American Association for the Study of Liver Disease treatment guidelines for hepatocellular carcinoma (HCC), the role of surgery has been expanded beyond the Barcelona Clinic Liver Cancer (BCLC) algorithm. We compared primary hepatectomy (PH) with transarterial chemoembolization (TACE) in patients with intermediate to advanced (BCLC stage-B/C) stage HCC to determine the current evidence. Through database search, we included 18 high-quality studies (1 randomized controlled trial [RCT], 5 propensity-score matching non-randomized comparative trials [NRCT], and 12 NRCTs) that compared survival outcomes of 5,986 patients after PH and TACE...
March 15, 2018: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29540482/pharmacologically-targeting-the-myristoylation-of-the-scaffold-protein-frs2%C3%AE-inhibits-fgf-fgfr-mediated-oncogenic-signaling-and-tumor-progression
#18
Qianjin Li, Omar Awad Alsaidan, Yongjie Ma, Sungjin Kim, Junchen Liu, Thomas Albers, Kebin Liu, Zanna Beharry, Shaying Zhao, Fen Wang, Iryna Lebedyeva, Houjian Cai
Fibroblast growth factor (FGF)/FGF receptor (FGFR) signaling facilitates tumor initiation and progression. Although currently approved inhibitors of FGFR kinase have shown therapeutic benefit in clinical trials, over-expression or mutations of FGFRs eventually confer drug resistance and thereby abrogate the desired activity of kinase inhibitors in many cancer types. In this study, we report that loss of myristoylation of fibroblast growth factor receptor substrate 2 (FRS2α), a scaffold protein essential for FGFR signaling, inhibits FGF/FGFR-mediated oncogenic signaling and FGF10-induced tumorigenesis...
March 14, 2018: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/29539626/risk-of-liver-toxicity-with-nivolumab-immunotherapy-in-cancer-patients
#19
Kevin Zarrabi, Shenhong Wu
BACKGROUND: Nivolumab is approved for the treatment of many cancers. This meta-analysis was conducted to determine the risk of hepatotoxicity with nivolumab therapy. METHODS: An analysis from all phase I-III clinical trials up to December 2016 examining nivolumab was conducted. Data on elevations in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were extracted from the safety profiles of each trial. Incidence and relative risk (RR) were calculated using random- or fixed-effects models with 95% confidence intervals (CIs)...
March 14, 2018: Oncology
https://www.readbyqxmd.com/read/29531324/differential-histopathologic-parameters-in-colorectal-cancer-liver-metastases-resected-after-triplets-plus-bevacizumab-or-cetuximab-a-pooled-analysis-of-five-prospective-trials
#20
Chiara Cremolini, Massimo Milione, Federica Marmorino, Federica Morano, Gemma Zucchelli, Alessia Mennitto, Michele Prisciandaro, Sara Lonardi, Alessio Pellegrinelli, Daniele Rossini, Francesca Bergamo, Giuseppe Aprile, Lucio Urbani, Luca Morelli, Marta Schirripa, Giovanni Gerardo Cardellino, Matteo Fassan, Gabriella Fontanini, Filippo de Braud, Vincenzo Mazzaferro, Alfredo Falcone, Filippo Pietrantonio
BACKGROUND: Many factors, including histopathologic parameters, seem to influence the prognosis of patients undergoing resection of colorectal cancer liver metastases (CRCLM), although their relative weight is unclear. Histopathologic growth patterns (HGPs) of CRCLM may affect sensitivity to antiangiogenics. We aimed at evaluating differences in histopathologic parameters of response according to the use of bevacizumab or cetuximab as first-line targeted agents, and at exploring the prognostic and predictive role of HGPs...
March 13, 2018: British Journal of Cancer
keyword
keyword
28809
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"